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Abstract 
The histrelin implant has emerged as a therapeutic option for the treatment of central precocious 
puberty (CPP) that has been favorably received by patients and providers. Inserted subcutaneously, 
the 50 mg implant provides continuous release of the potent gonadotropin releasing hormone 
analog (GnRHa) histrelin. Profound suppression of the hypothalamic-pituitary-gonadal (HPG) 
axis occurs within one month of its placement resulting in pubertal arrest, attenuation of skeletal 
advancement and a progressive increase in predicted adult height.  Although marketed for annual 
use, suppression lasting two years from a single implant has been demonstrated. Placing and 
removing the device is a minor outpatient procedure easily accomplished by a pediatric surgeon 
using local anesthesia. The major downside to the implant is a ~25% rate of breakage upon 
removal. Information about recovery of the HPG axis following histrelin explanation is limited 
but suggests an average time to menarche comparable with depot-GnRHa formulations albeit with 
wide individual variation.  
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Introduction 
The histrelin subcutaneous implant was approved for the treatment of central precocious 
puberty (CPP) in the US in 2007[1]. The implant, which is constructed of a flexible non-
biodegradable hydrogel, provides continuous release of the drug across microporous walls. The 
synthetic gonadotropin releasing hormone analog (GnRHa) histrelin is > 200 times more potent 
than native GnRH and has been commercially available for more than two decades[2]. However, 
because it previously required daily subcutaneous administration, histrelin became largely 
obsolete once monthly depot GnRHa preparations were developed [3].  Histrelin reemerged in the 
therapeutic armamentarium in the form of a yearly implant for the treatment of prostate cancer[4], 
which paved the way for studies in children with CPP[5]. Although the implants prescribed for 
these two indications both contain 50 mg of drug, the device developed for children allows for a 
more rapid release of histrelin than the one used in adults (65 mcg/d vs 41 mcg/d). The device is 
inserted using a trocar, usually by a pediatric surgeon. Although the majority of centers perform 
the procedure using local anesthesia, conscious sedation and general anesthesia have also been 
utilized in select cases. Since its approval, the histrelin implant has rapidly increased in popularity 
in the United States and is now well-established as a highly efficacious treatment[6]. However, 
data regarding long-term follow-up of children treated with this modality are not yet available[7]. 
Treatment of Central Precocious Puberty 
 The first report of the use of the histrelin implant in children involved a pilot study of 11 
girls with CPP, all of whom had previously been treated with a depot GnRHa preparation[8]. Serial 
GnRH stimulation tests demonstrated lower gonadotropin levels after insertion of the implant than 
on the depot GnRHa with continued HPG axis suppression throughout the treatment course. No 
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difference in biochemical or clinical parameters was seen in patients in whom the implant was 
replaced at 9 months (n=5) versus at 15 months (n=6). Quality of life questionnaires found 
significantly lower rates of discomfort/pain and less disruption of activities during treatment with 
the implant than with depot GnRHa intramuscular injections. Following this small trial, an open-
label phase III multicenter study was undertaken that involved 36 children (3 boys) from 9 different 
centers, 20 of whom were naïve to GnRHa therapy. In both naïve and previously treated patients, 
peak stimulated LH significantly decreased within one month, and estradiol suppressed to 
prepubertal levels in naïve girls. Linear growth velocity and the ratio of bone age to chronological 
age (BA/CA) also declined during the initial year of treatment, while BMI percentiles remained 
stable [9]. Two year results in 31 children from this same trial demonstrated a further decline in 
peak stimulated LH at 24 months compared with 12 months as well as an increase in predicted 
adult height (PAH) of 5.1 cm[10]. Final results from the extension phase of this multicenter study 
are now available. In children completing 6 years of treatment with sequential histrelin implants, 
pubertal suppression was maintained, BA/CA progressively decreased and PAH increased. The 
greatest gain was observed in treatment- naïve children, who experienced an increase of 10.5 cm 
in PAH at the end of the trial. No adverse effect on growth velocity or HPG axis recovery was 
seen, and the implant was well tolerated overall[11].  
 An important advance in the use of the histrelin implant for CPP was the demonstration 
that a single implant is effective for two years. This was based on the recognition that if 65 mcg 
of drug is released each day, a 50 mg implant should theoretically contain ample histrelin to 
maintain HPG suppression for 769 days, or exactly two years. That this is indeed the case was 
established by a study involving 33 children with CPP in whom a single implant was left in situ 
for two years. Peak stimulated LH at 12 and 24 months was equivalent whereas radiographic and 
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clinical indices of puberty progressively improved[12].  Use of a single implant for two years has 
the distinct advantage of significantly decreasing cost and numbers of surgical procedures, and 
thus has become standard practice at many institutions (personal communication). 
Surgical and Anesthetic Considerations 
 A systematic review of one surgeon’s experience with histrelin implant procedures largely 
corroborates what has been reported in clinical trials. Of 114 cases, ~50% were implantations, 25% 
were explantations and 25% were removals followed by insertion of a new implant. The vast 
majority (95%) of procedures were performed using local anesthesia, with general anesthesia 
employed primarily in neurologically-impaired children[13]. Inhaled nitrous oxide was utilized to 
augment local anesthesia in this series, although distraction using “child life” personnel is a less 
invasive and highly successful alternative approach (personal experience). At this author’s 
institution, procedures involving the histrelin implant are also performed primarily by a single 
pediatric surgeon. Our surgeon reports an average duration of 16.6 minutes, although with a range 
of 3-55 minutes. A longer duration has been noted if the procedure is removal of an implant versus 
placement (21.6 minutes versus 10 minutes, p<0.0001, unpublished data). 
Safety 
 Minor implant site reactions are the most common adverse event reported in patients 
treated with the histrelin implant and occur in ~50% of patients. These are self-limited and resolve 
spontaneously. The most troubling safety concern associated with the implant has been a relatively 
high rate of implant breakage and or difficulty with localization. These issues are limited to the 
explantation procedure and appear to be due to encapsulation of the device or the presence of scar 
tissue. Anecdotally, implants appear to become quite desiccated and brittle in some children 
(personal communication) although individual patient characteristics that predict these problems 
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have not been identified. Depending on the study, the rate of implant breakage ranges from 22-
39% and is higher when left in place for two years.  Other rarely reported complications have 
included infection, implant extrusion and keloid scar formation [5]. When intact or partial implants 
are difficult to localize due to fracture or migration from the insertion site, ultrasonography has 
been reported to be an effective modality to aid in the retrieval process[14].  
Monitoring 
The optimal strategy for monitoring therapy in children being treated for CPP has not been 
identified, and clinical practice varies significantly among providers. While there is general 
consensus regarding the importance of following clinical and auxological parameters such as 
Tanner staging, growth velocity and skeletal maturation, the role of routine hormonal 
measurements is controversial [15]. The shortage of synthetic GnRH in the US has led to 
alternative approaches for both the diagnosis and monitoring of children with CPP. One of these 
has been the use of random ultrasensitive LH values, which have been shown to correlate well 
with peak stimulated LH at the time of initial presentation [16].  Given the inherent appeal of a 
simpler and less invasive option than a full stimulation test, it is perhaps not surprising that random 
LH concentrations have also been applied to the monitoring arena. Interestingly, however, random 
LH has been shown to often remain in a pubertal range even in patients who have a fully suppressed 
HPG axis by every other criteria[17]. This phenomenon has been demonstrated during treatment 
with the histrelin implant as well as with depot leuprolide injections[18]. Thus, random 
ultrasensitive LH measurements do not have a place in the monitoring of children undergoing 
treatment for CPP. Whether any biochemical assessments aid in the management of children with 
CPP who are responding as expected to GnRHa treatment remains to be seen.  
Recovery of the HPG Axis 
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Limited information is available thus far regarding recovery of the HPG axis following 
treatment with the histrelin implant. In one study, time from explantation to menarche was 
determined in 11 girls, all but 2 of whom were previously treated with depot GnRHa injections, 
and was compared to 23 girls treated only with depot GnRHa. The average time to menarche was 
significantly shorter in the histrelin group compared with the injection group (9.3 vs 16 months, 
p=0.02)[19].  In contrast, a larger study involving 30 girls with CPP found an average interval 
from implant removal to menarche of 12.75 months, albeit with significant individual variation. 
Of all variables analyzed, only older age at explantation correlated with a shorter duration to 
menarche. All boys experienced an increase in testicular volume within one year of cessation of 
histrelin implant therapy[20]. While a peak stimulated LH >4 mIU/mL is clearly indicative of re-
activation of the reproductive system, there is evidence that free alpha subunit might represent the 
earliest detectable biochemical change following removal of the histrelin implant. Rising 
paradoxically during treatment, free alpha subunit concentrations have been shown to fall rapidly 
upon removal of the implant, preceding changes in sex steroids and gonadotropins by several 
weeks [21]. An additional advantage of this test is the ability to use it to determine whether an 
implant has been completely removed in cases where there has been breakage or difficulty with 
localization.  
Future Directions 
 Many questions remain regarding the histrelin implant. In the short-term, the absolute 
upper-limit of efficacy of the device has not been established. While the implant clearly lasts for 
at least two years, continued suppression of the HPG axis beyond this is theoretically possible. A 
second logical question is whether the device could be altered in some way as to make breakage 
and/or problems with localization less of a problem.  Additionally, although there are significant 
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data regarding long-term follow-up of children treated with depot GnRHa [22], essentially no such 
information exists for the histrelin implant. Outcomes of interest include but are not limited to, 
reproductive function, bone mineral density and BMI. Whether CPP is associated with significant 
psychological problems and, if so, whether treatment with the histrelin implant or other GnRHa 
formulations alleviates these issues are also areas in which a deficit of knowledge exists[23]. 
Finally, it will be interesting to observe to what extent the histrelin implant is embraced as a 
therapeutic modality for CPP in Europe and other parts of the world as compared to its popularity 
in the US.  
Conclusions 
 Although the histrelin implant is a relative newcomer to the cadre of GnRHa preparations 
for the treatment of CPP, studies conducted thus far have consistently demonstrated excellent 
efficacy of the device in terms of pubertal suppression, including when a single implant is left in 
place for two years. While generally well-tolerated, implant breakage and or problems with 
localization occur in approximately one fourth of patients at the time of removal. Large scale 
prospective studies will provide additional important information regarding efficacy, safety and 
long-term outcomes of children being treated with the histrelin implant for CPP.  
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